Please login to the form below

Not currently logged in
Email:
Password:

inflammatory disorders

This page shows the latest inflammatory disorders news and features for those working in and with pharma, biotech and healthcare.

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Heading the pack is IFM-2427, an NLRP3 antagonist that has just started a phase 1 clinical trial in healthy volunteers and has potential in chronic inflammatory disorders, including gout, atherosclerosis ... a role in neurological conditions with

Latest news

More from news
Approximately 1 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    disorders. With a headline value of $102.25m, Receptor will be undertaking manufacture and commercialisation. ... 150. MannKind/ Receptor Life Sciences. Licence, collaboration. Multiple inhaled therapeutic products for conditions such as chronic pain,

  • Pharma deals during April 2014 Pharma deals during April 2014

    premium. This gives Mallinckrodt, Acthar Gel (repository corticotropin), which is FDA approved for 19 “difficult-to-treat” autoimmune and inflammatory associated conditions and currently primarily used to treat multiple sclerosis relapses,

  • Pharma deals during March 2013 Pharma deals during March 2013

    25. Five Prime Therapeutics/ UCB. Option to license. Protein discovery platform - up to 5 programmes for fibrosis-related inflammatory diseases and CNS disorders.

  • Interview: Michel Goldman, Innovative Medicines Initiative Interview: Michel Goldman, Innovative Medicines Initiative

    And we do this by implementing proposals in different areas. For example, we have several projects on brain disorders, diabetes, cancer, inflammatory disorders and several projects on pulmonary diseases, to give ... His achievements in the fields of

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

    He has 30 years’ experience in research and development specifically in gastrointestinal disorders, inflammatory diseases and cancers, and previously co-founded Synergy Pharmaceuticals and served as its chief scientific officer.

  • Karus names two division heads Karus names two division heads

    Most recently he was VP, global head – respiratory disease. In his new role Dr Finan will work on Karus' most advanced programme, a treatment for inflammatory disorders.

  • Merck KGaA appoints biosimilar head Merck KGaA appoints biosimilar head

    From March 1, Sturge will run the company's biosimilars division, which was set up in 2012 to develop copies of biological treatments with a focus on oncology and inflammatory disorders. .

  • Questcor appoints SVP corporate strategic development Questcor appoints SVP corporate strategic development

    His main responsibilities will include identifying potential partnerships and acquisitions for the company, which specialises in developing treatments for difficult-to-treat autoimmune and inflammatory disorders.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics